1. Market Research
  2. > Pathology
68 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • Australia

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • January 2019
  • 201 pages

ALTHOUGH CELLTRION' S TRUXIMA WAS SIMILARLY TREATED BY THE FDA, THE COMPANY COMPLIED WITH REQUESTS FOR ADDITIONAL DATA AND IN NOVEMBER 2018, CELLTRION' S TRUXIMA WAS APPROVED, BUT ONLY FOR THE TREATMENT OF B-CELL NON-HODGKIN AND FOLLICULAR LYMPHOMAS (CELLTRION, PRESS RELEASE, ## NOV

  • Biosimilar
  • Hospital
  • Lymphoma
  • Therapy
  • Australia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia

  • $ 1995
  • November 2019
  • 180 pages

It also discontinued GSK-## in Phase I stage of development for follicular lymphoma, diffuse large Bcell lymphoma, solid tumor, and refractory multiple myeloma.

  • Lymphoma
  • Medical Device
  • Medical Equipment
  • Pharmaceutical
  • Australia

Medical Marijuana - Thematic Research

  • $ 7995
  • November 2019
  • 186 pages

Medical Marijuana: Innovative Pipeline Shows Promise For Treating More Than ## Indications © GlobalData 2019 This product is licensed and is not to be photocopied.

  • Lymphoma
  • Marijuana
  • Neurological Disorder
  • Neurology
  • Australia

2024 Australia Hematology and Flow Cytometry Analyzers and Reagents Market: Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Competitive Landscape, Emerging Technologies, Instrumentation and Opportunities

  • $ 1450
  • July 2020
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Australasia
  • Australia

Australia Hematology and Flow Cytometry Analyzers and Reagents Market for Over 40 Tests: Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 750
  • September 2019
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Australasia
  • Australia

Australia Hematology and Flow Cytometry Analyzers and Reagents Market, 2019-2023: Supplier Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 750
  • June 2019
  • 225 pages

Flow Cytometry Tests Analyzed in the Report Cell Surface Markers (CD##/ CD##/ TandB Lymphocytes, CD##, Others), Chemotherapy Monitoring (Leukemia/ Lymphoma, Others), HLA Typing, Sperm Analysis, Cell Cycle Kinetics, Cell Function Testing, Chromosomal Abnormalities, Fetal Cell Analy

  • Diagnostics
  • Lymphoma
  • Medical Biotechnology
  • Australasia
  • Australia

The Walter and Eliza Hall Institute of Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 66 pages

" It was amazing to find that the loss of the DNA repair gene MLH## prevented p## from functioning properly, causing the development of lymphoma.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Australia

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • February 2017
  • 403 pages

HOWEVER, PATIENTS WITH RA ARE KNOWN TO BE AT A HIGHER RISK FOR DEVELOPING LYMPHOMA.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Lymphoma
  • Australia

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 211 pages

The targeted subindications are mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Australia

Australia General Surgery Market Outlook to 2023 - Aesthetic Lasers and Energy Devices, Bariatric Surgery Devices, Biopsy Devices, Bronchoscopes, Colonoscopes, Cystoscopes, Duodenoscopes, Endoscopy Fluid Management Systems and Others

  • $ 5995
  • May 2017
  • 564 pages

LYMPHOMA CONSUMERS AND HEALTH PROFESSIONALS ARE ADVISED THAT THE TGA HAS CONTINUED TO MONITOR THE ASSOCIATION BETWEEN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) AND BREAST IMPLANTS SINCE WE PUBLISHED A SAFETY COMMUNICATION REGARDING THIS ISSUE ON ## JANUARY 2011.

  • Biopsy
  • Endoscope
  • Lymphoma
  • Australasia
  • Australia

Kaposi Sarcoma - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 294 pages

IT IS IN PHASE I STAGE OF DEVELOPMENT FOR DIFFUSE LARGE B CELL LYMPHOMA AND HIGH-GRADE B CELL LYMPHOMA.

  • Chemotherapy
  • Hospital
  • Lymphoma
  • Therapy
  • Australia

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • September 2017
  • 433 pages

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026 Summary Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, ...

  • Hospital
  • Lymphoma
  • Therapy
  • Australia
  • Merck & Co., Inc.

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019
  • 190 pages

The targeted subindications are mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Australia

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H1 2019

  • $ 3500
  • June 2019
  • 86 pages

As of October 2014, it was in Phase I stage for advanced solid tumors and lymphomas as first line of therapy.

  • Cancer
  • Lymphoma
  • Oncology
  • Therapy
  • Australia

High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 138 pages

IT IS IN PHASE II FOR ANAPLASTIC LARGE CELL LYMPHOMA, LEPTOMENINGEAL DISEASE, METASTATIC PANCREATIC CANCER, CHOLANGIOCARCINOMA, PAPILLARY THYROID CANCER, TRIPLE NEGATIVE, HER-## POSITIVE, ER OR PR POSITIVE BREAST CANCER AND METASTATIC MELANOMA.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • Therapy
  • Australia

Rhabdomyosarcoma - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 421 pages

The hematologic cancers to be studied include multiple myeloma (MM), chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/ SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and potentially diffuse la

  • Hospital
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Australia

Heparanase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 43 pages

Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas.

  • Lymphoma
  • Therapy
  • Australia
  • Product Initiative
  • Progen Pharmaceuticals Limited

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2020

  • $ 2000
  • June 2020
  • 627 pages

IT IS IN PHASE I STAGE OF DEVELOPMENT FOR DIFFUSE LARGE B CELL LYMPHOMA AND HIGH-GRADE B CELL LYMPHOMA.

  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Australia

E3 Ubiquitin Protein Ligase XIAP - Pipeline Review, H2 2019

  • $ 3500
  • November 2019
  • 83 pages

AS OF OCTOBER 2014, IT WAS IN PHASE I STAGE FOR ADVANCED SOLID TUMORS AND LYMPHOMAS AS FIRST LINE OF THERAPY.

  • Cancer
  • Lymphoma
  • Oncology
  • Therapy
  • Australia
View report >

Cancer Statistics

  • February 2020
  • 66 pages

Salivary gland Polycythaemia vera Oropharynx Other lymphomas Thymus Eye Nose, nasal cavities, middle ear and accessory sinuses Larynx Other endocrine glands Skin of anus (including perineum, perianal skin) Nasopharynx Malignancy of histiocytes and accessory lymphoid cells Unspecified sites

  • Cancer
  • Lymphoma
  • Pathology
  • Australia
  • Demographic

Cancer Statistics June 2019

Cancer Statistics January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on